IP Library Patent Application 11606617
Patent Application
App. No. 11/606,617

Heat mitigating hemostatic agent

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/606,617
Abstract

A hemostatic agent in the form of particles comprises a first component and a second component bound thereto, each component having hemostatic properties. Additional components may also be included. The first component may be a zeolite and the second component may be clay. A device for promoting the clotting of blood comprises a receptacle for retaining particles of a hemostatic agent therein, at least a portion of the receptacle being defined by a mesh. A pad for controlling bleeding comprises a mesh structure defined by openings sized to accommodate the flow of blood therethrough and also by a hemostatic agent retained in the mesh structure. A bandage applicable to a bleeding wound comprises a substrate, a mesh mounted on the substrate, and a hemostatic agent retained in the mesh. The mesh is defined by a plurality of members arranged to define openings through which blood may flow.

Claims (60)

1 . A hemostatic agent, comprising:

a particle comprising,

a first component having hemostatic properties, and

a second component having hemostatic properties, said second component binding said first component;

wherein said first component and said second component are uniformly and homogenously mixed in amounts to modulate an exothermic reaction when said hemostatic agent is applied to blood; and

wherein when using said hemostatic agent to treat a bleeding wound, contacting said bleeding wound with said hemostatic agent causes blood flowing from said bleeding wound to clot.

2 . The hemostatic agent of claim 1 , wherein said first component is a zeolite.

3 . The hemostatic agent of claim 1 , wherein said second component is a clay.

4 . The hemostatic agent of claim 3 , wherein said clay is kaolin.

5 . The hemostatic agent of claim 4 , wherein said kaolin is Edgar's plastic kaolin.

6 . The hemostatic agent of claim 3 , wherein said clay is selected from the group consisting of attapulgite, bentonite, kaolin, and combinations of the foregoing.

7 . The hemostatic agent of claim 1 , wherein said particle is in a form of a bead, a rod, a granule, or has an irregular surface morphology.

8 . The hemostatic agent of claim 1 , wherein particle is about 0.2 mm to about 10 mm in effective diameter.

9 . The hemostatic agent of claim 1 , wherein particle is about 0.5 mm to about 5 mm in effective diameter.

10 . The hemostatic agent of claim 1 , wherein particle is about 1 mm to about 2 mm in effective diameter.

11 . The hemostatic agent of claim 1 , further comprising a third component incorporated into said particle, said third component having a property that is at least one of antibiotic, antifungal, anti-infective, antimicrobial, anti-inflammatory, analgesic, antihistamine, wound healing, and hemostatic.

12 . The hemostatic agent of claim 1 , wherein at least one of said first component and said second component is selected from the group consisting of bioactive glasses, siliceous oxides, diatomaceous earth, and combinations of the foregoing.

13 . A device for promoting the clotting of blood, comprising:

a receptacle, at least a portion of said receptacle being defined by a mesh having openings therein,

a hemostatic agent retained in said receptacle, said hemostatic agent comprising particles, each particle having a first component having hemostatic properties and a second component having hemostatic properties, said second component binding said first component;

wherein said first component and said second component are uniformly and homogenously mixed in amounts to modulate an exothermic reaction when said hemostatic agent is applied to blood; and

wherein when treating a bleeding wound, application of said device causes at least a portion of said hemostatic agent to come into contact with blood through said openings.

14 . The device for promoting the clotting of blood of claim 13 , wherein said first component is a zeolite.

15 . The device for promoting the clotting of blood of claim 13 , wherein said second component is a clay.

16 . The device for promoting the clotting of blood of claim 15 , wherein said clay is selected from the group consisting of attapulgite, bentonite, kaolin, and combinations of the foregoing.

17 . The device for promoting the clotting of blood of claim 15 , wherein said clay is kaolin.

18 . The device for promoting the clotting of blood of claim 13 , wherein said particles are in the forms of beads, rods, granules, or have irregular surface morphologies.

19 . The device for promoting the clotting of blood of claim 13 , wherein at least one of said first component and said second component is selected from the group consisting of bioactive glasses, siliceous oxides, diatomaceous earth, and combinations of the foregoing.

20 . The device for promoting the clotting of blood of claim 13 , wherein said particle of said hemostatic agent further comprises a third component, said third component having a property that is at least one of antibiotic, antifungal, anti-infective, antimicrobial, anti-inflammatory, analgesic, antihistamine, wound healing, and hemostatic.

21 . The device for promoting the clotting of blood of claim 13 , wherein said mesh structure is flexible.

22 . The device for promoting the clotting of blood of claim 13 , wherein at least one particle of said hemostatic agent protrudes through one of said openings.

23 . The device for promoting the clotting of blood of claim 13 , wherein the effective diameters of the particles are about 0.2 mm to about 10 mm.

24 . The device for promoting the clotting of blood of claim 13 , wherein the effective diameters of the particles are about 0.5 mm to about 5 mm.

25 . The device for promoting the clotting of blood of claim 13 , wherein the effective diameters of the particles are about 1 mm to about 2 mm.

26 . A pad for controlling bleeding, comprising:

a mesh structure defined by openings sized to accommodate the flow of blood therethrough;

a hemostatic agent retained in said mesh structure, said hemostatic agent comprising particles, each particle having a first component having hemostatic properties and a second component having hemostatic properties, said second component binding said first component;

wherein said first component and said second component are uniformly and homogenously mixed in amounts to modulate an exothermic reaction when said hemostatic agent is applied to blood; and

wherein when treating a bleeding wound, application of said pad causes at least a portion of said hemostatic agent to come into contact with blood through said openings.

27 . The pad of claim 26 , wherein said first component is a zeolite and wherein said second component is a clay.

28 . The pad of claim 27 , wherein said clay is selected from the group consisting of attapulgite, bentonite, kaolin, and combinations of the foregoing.

29 . The pad of claim 27 , wherein said clay is kaolin.

30 . The pad of claim 26 , wherein said particles are in the forms of beads, rods, granules, or have irregular surface morphologies.

31 . The pad of claim 26 , wherein at least one of said first component and said second component is selected from the group consisting of bioactive glasses, siliceous oxides, diatomaceous earth, and combinations of the foregoing.

32 . The pad of claim 26 , wherein said particle of said hemostatic agent further comprises a third component, said third component having a property that is at least one of antibiotic, antifungal, anti-infective, antimicrobial, anti-inflammatory, analgesic, antihistamine, wound healing, and hemostatic.

33 . The pad of claim 26 , wherein said particles of said hemostatic agent each have effective diameters of about 0.2 mm to about 10 mm.

34 . The pad of claim 26 , wherein said particles of said hemostatic agent each have effective diameters of about 0.5 mm to about 5 mm.

35 . The pad of claim 26 , wherein said particles of said hemostatic agent each have effective diameters of about 1 mm to about 2 mm.

36 . The pad of claim 26 , further comprising a support attached to said mesh structure, said support being configured to have a pressure applied thereto to enable said pad to be retained on a bleeding wound.

37 . A bandage applicable to a bleeding wound, said bandage comprising:

a substrate;

a mesh mounted on said substrate, said mesh being defined by a plurality of members arranged to define openings, said openings being dimensioned to accommodate the flow of blood therethrough; and

a hemostatic agent retained in said mesh, said hemostatic agent comprising particles, each particle having a first component having hemostatic properties and a second component having hemostatic properties, said second component binding said first component, said first component and said second component being uniformly and homogenously mixed in amounts to modulate an exothermic reaction when said hemostatic agent is applied to blood.

38 . The bandage of claim 37 , further comprising an adhesive on said substrate, said adhesive being configured to facilitate the retaining of said bandage on the skin of a wearer.

39 . The bandage of claim 37 , wherein said first component is a zeolite and said second component is a clay.

40 . The bandage of claim 39 , wherein said clay is selected from the group consisting of attapulgite, bentonite, kaolin, and combinations of the foregoing.

41 . The bandage of claim 39 , wherein said clay is kaolin.

42 . The bandage of claim 37 , wherein said particles are in the forms of beads, rods, granules, or have irregular surface morphologies.

43 . The bandage of claim 37 , wherein at least one of said first component and said second component is selected from the group consisting of bioactive glasses, siliceous oxides, diatomaceous earth, and combinations of the foregoing.

44 . The bandage of claim 37 , wherein said particle of said hemostatic agent further comprises a third component, said third component having a property that is at least one of antibiotic, antifungal, anti-infective, antimicrobial, anti-inflammatory, analgesic, antihistamine, wound healing, and hemostatic.

Assignments (7)
CHANGE OF NAME Recorded Feb 29, 2024
From: TELEFLEX TECHNOLOGIES LLC
To: TELEFLEX LIFE SCIENCES II LLC
Reel/Frame 066836/0737 →
MERGER Recorded Feb 29, 2024
From: TELEFLEX LIFE SCIENCES II LLC
To: TELEFLEX TECHNOLOGIES LLC
Reel/Frame 066707/0695 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: TELEFLEX LIFE SCIENCES LIMITED
To: TELEFLEX LIFE SCIENCES II LLC
Reel/Frame 066434/0248 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2022
From: Z-MEDICA, LLC
To: TELEFLEX LIFE SCIENCES LIMITED
Reel/Frame 058740/0387 →
MERGER Recorded Apr 1, 2015
From: Z-MEDICA CORPORATION
To: Z-MEDICA, LLC
Reel/Frame 035353/0423 →
SECURITY INTEREST Recorded Apr 1, 2015
From: Z-MEDICA, LLC
To: MADISON CAPITAL FUNDING LLC, AS AGENT
Reel/Frame 035308/0704 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2008
From: LO, DENNY
To: Z-MEDICA CORPORATION
Reel/Frame 021453/0621 →